THE TRUST STUDY

The TRUST study is a phase 1b trial designed to assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with Acute Decompensation (AD), or with ACLF Grades 1 and 2 with liver failure or coagulation failure and a range of renal function.

Patients are actively being recruited in Austria, Belgium, France, and Spain.

For a list of sites actively recruiting, please click on the link.

ACLF is a syndrome characterized by acute decompensation of chronic liver disease in combination with organ failures, resulting in high short-term mortality. The greater the number of organ systems involved, the higher the mortality rate. Despite current aggressive medical management, mortality at 30 and 90 days in ACLF remains high, ranging from about 50% in milder cases to nearly 80% in patients with 3 or more organ system failures.

The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0), or with ACLF Grades 1 and 2 with liver or coagulation failure and a range of renal function.

For more information on the study, please click on the link.